| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
RMD
Resmed
|
Jun 15, 2026 | BUY |
Buy
+26.6% avg upside
27 analysts
|
$270.00
45.03% Upside
|
+0.0% |
|
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
|
Jun 15, 2026 | BUY |
Strong Buy
+58.6% avg upside
11 analysts
|
$38.00
43.33% Upside
|
· |
|
AU:CSL
CSL
|
May 14, 2026 | HOLD |
Strong Buy
+71.0% avg upside
15 analysts
|
$110.00
1.84% Upside
|
· |
|
AU:TLX
Telix Pharmaceuticals
|
Apr 29, 2026 | BUY |
Strong Buy
+77.4% avg upside
13 analysts
|
$32.00
123.56% Upside
|
· |
|
AU:COH
Cochlear
|
Apr 22, 2026 | SELL |
Hold
+55.5% avg upside
15 analysts
|
$95.00
16.83% Downside
|
· |
|
AU:PME
Pro Medicus Limited
|
Apr 06, 2026 | BUY |
Strong Buy
+55.0% avg upside
7 analysts
|
$245.00
46.21% Upside
|
· |
|
AU:RHC
Ramsay Health Care
|
Mar 30, 2026 | HOLD |
Hold
+2.3% avg upside
14 analysts
|
$39.00
0.81% Downside
|
· |
|
AU:SHL
Sonic Healthcare Limited
|
Mar 19, 2026 | HOLD |
Buy
+30.5% avg upside
11 analysts
|
$21.50
8.40% Upside
|
· |
|
AU:ANN
Ansell
|
Mar 18, 2026 | HOLD |
Buy
+13.0% avg upside
9 analysts
|
$36.00
20.96% Upside
|
· |
|
NL:LKFT
Galapagos
|
May 07, 2024 | HOLD |
Sell
+112.0% avg upside
16 analysts
|
$34.00
37.42% Upside
|
· |
|
CH:NOVN
Novartis AG
|
Dec 14, 2022 | HOLD |
Buy
-11.2% avg upside
30 analysts
|
$84.00
30.43% Downside
|
· |
|
FR:SAN
Sanofi
|
Aug 09, 2022 | HOLD |
Strong Buy
+33.5% avg upside
29 analysts
|
$103.00
38.89% Upside
|
· |
|
SAN
Banco Santander SA
|
Aug 09, 2022 | HOLD |
Buy
-46.9% avg upside
7 analysts
|
— | +55.6% |
|
GB:GSK
GlaxoSmithKline
|
Aug 08, 2022 | HOLD |
Hold
-4.4% avg upside
25 analysts
|
$1820.00
7.41% Downside
|
· |
|
GB:0NZT
UCB SA
|
Jun 27, 2022 | HOLD |
Buy
-13.5% avg upside
19 analysts
|
$87.00
65.17% Downside
|
· |
|
GB:0MGB
Genmab A/S
|
May 20, 2022 | BUY |
Buy
+34.6% avg upside
22 analysts
|
$2600.00
61.08% Upside
|
· |
|
GMAB
Genmab
|
Mar 16, 2022 | BUY |
Buy
+38.1% avg upside
26 analysts
|
— | +0.5% |
|
NVS
Novartis
|
Nov 05, 2021 | HOLD |
Hold
-9.3% avg upside
24 analysts
|
— | +1.8% |
|
ARGX
Argenx Se
|
Jun 18, 2021 | BUY |
Strong Buy
-16.4% avg upside
46 analysts
|
$390.00
56.39% Downside
|
+10.0% |
|
LKFT
Lakefront Biotherapeutics
|
Apr 12, 2021 | HOLD |
Hold
+272.1% avg upside
24 analysts
|
$89.42
215.20% Upside
|
· |
|
DE:MRK
Merck KGaA
|
Feb 28, 2020 | HOLD |
Buy
-1.1% avg upside
31 analysts
|
$108.00
18.41% Downside
|
· |
|
SNY
Sanofi
|
Aug 14, 2019 | BUY |
Strong Buy
+74.1% avg upside
20 analysts
|
— | +25.0% |
|
GSK
GlaxoSmithKline
|
Feb 22, 2019 | HOLD |
Hold
-16.3% avg upside
19 analysts
|
— | +11.6% |
|
NVO
Novo Nordisk
|
Aug 08, 2018 | HOLD |
Buy
+166.9% avg upside
26 analysts
|
$300.00
589.40% Upside
|
+10.3% |
|
LLY
Eli Lilly & Co
|
Jul 25, 2018 | HOLD |
Strong Buy
-11.3% avg upside
47 analysts
|
$99.00
91.11% Downside
|
+14.2% |
|
BMY
Bristol-Myers Squibb
|
Oct 26, 2017 | HOLD |
Buy
+7.4% avg upside
42 analysts
|
$55.00
0.44% Downside
|
-15.0% |
|
GILD
Gilead Sciences
|
Oct 18, 2017 | BUY |
Strong Buy
-5.7% avg upside
66 analysts
|
$96.00
23.44% Downside
|
-4.5% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.